ATE340562T1 - Cgmp pde-5 inhibitor enthaltende pharmazeutische formulierungen mit verzögerter freisetzung - Google Patents

Cgmp pde-5 inhibitor enthaltende pharmazeutische formulierungen mit verzögerter freisetzung

Info

Publication number
ATE340562T1
ATE340562T1 AT99946377T AT99946377T ATE340562T1 AT E340562 T1 ATE340562 T1 AT E340562T1 AT 99946377 T AT99946377 T AT 99946377T AT 99946377 T AT99946377 T AT 99946377T AT E340562 T1 ATE340562 T1 AT E340562T1
Authority
AT
Austria
Prior art keywords
inhibitor
pharmaceutical formulations
formulations containing
delayed release
release pharmaceutical
Prior art date
Application number
AT99946377T
Other languages
English (en)
Inventor
Elizabeth King
Ross James Macrae
Original Assignee
Pfizer Ireland Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269526&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE340562(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9823192.1A external-priority patent/GB9823192D0/en
Priority claimed from GBGB9825117.6A external-priority patent/GB9825117D0/en
Priority claimed from GBGB9826392.4A external-priority patent/GB9826392D0/en
Application filed by Pfizer Ireland Pharmaceuticals filed Critical Pfizer Ireland Pharmaceuticals
Application granted granted Critical
Publication of ATE340562T1 publication Critical patent/ATE340562T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99946377T 1998-10-23 1999-10-04 Cgmp pde-5 inhibitor enthaltende pharmazeutische formulierungen mit verzögerter freisetzung ATE340562T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9823192.1A GB9823192D0 (en) 1998-10-23 1998-10-23 Pharmaceutical formulations
GBGB9825117.6A GB9825117D0 (en) 1998-11-16 1998-11-16 Pharmaceutical formulations
GBGB9826392.4A GB9826392D0 (en) 1998-11-27 1998-11-27 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
ATE340562T1 true ATE340562T1 (de) 2006-10-15

Family

ID=27269526

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99946377T ATE340562T1 (de) 1998-10-23 1999-10-04 Cgmp pde-5 inhibitor enthaltende pharmazeutische formulierungen mit verzögerter freisetzung

Country Status (44)

Country Link
US (1) US6964780B1 (de)
EP (1) EP1123088B1 (de)
JP (1) JP2002528408A (de)
KR (1) KR20010075659A (de)
CN (1) CN1324233A (de)
AP (1) AP2001002125A0 (de)
AT (1) ATE340562T1 (de)
AU (1) AU756509B2 (de)
BG (1) BG65323B1 (de)
BR (1) BR9914718A (de)
CA (1) CA2348086C (de)
CO (1) CO5160262A1 (de)
CR (1) CR6326A (de)
CY (1) CY1106239T1 (de)
CZ (1) CZ20011427A3 (de)
DE (1) DE69933383T2 (de)
DK (1) DK1123088T3 (de)
DZ (1) DZ2923A1 (de)
EA (1) EA004068B1 (de)
EE (1) EE200100235A (de)
ES (1) ES2272082T3 (de)
GT (1) GT199900184A (de)
HK (1) HK1041818A1 (de)
HR (1) HRP20010285A2 (de)
HU (1) HUP0104318A3 (de)
ID (1) ID28232A (de)
IL (1) IL141764A (de)
IS (1) IS5865A (de)
MA (1) MA26700A1 (de)
MX (1) MXPA01004011A (de)
MY (1) MY130727A (de)
NO (1) NO20011933L (de)
NZ (1) NZ510275A (de)
OA (1) OA11664A (de)
PA (1) PA8484301A1 (de)
PE (1) PE20001286A1 (de)
PL (1) PL195789B1 (de)
PT (1) PT1123088E (de)
SK (1) SK286473B6 (de)
TR (1) TR200101103T2 (de)
TW (1) TW577756B (de)
UA (1) UA67802C2 (de)
UY (1) UY25765A1 (de)
WO (1) WO2000024383A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ504436A (en) * 1997-11-12 2001-08-31 Bayer Ag 2-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
DK1126826T6 (en) 1998-11-02 2019-06-24 Alkermes Pharma Ireland Ltd Multiparticulate modified release of methylphenidate
JP4806507B2 (ja) 1999-10-29 2011-11-02 ユーロ−セルティーク エス．エイ． 制御放出ヒドロコドン処方
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
MXPA03001958A (es) 2000-09-06 2003-06-24 Tanabe Seiyaku Co Preparaciones para administrar oral.
CN101653411A (zh) 2000-10-30 2010-02-24 欧罗赛铁克股份有限公司 控释氢可酮制剂
JP4179784B2 (ja) * 2001-02-15 2008-11-12 田辺三菱製薬株式会社 口腔内速崩壊性錠
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
ITMI20020515A1 (it) * 2002-03-12 2003-09-12 Jagotec Ag Sistema per il rilasco controllato di uno o piu' principi attivi
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
NZ551356A (en) 2004-05-11 2009-09-25 Emotional Brain Bv Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
GB0421121D0 (en) * 2004-09-22 2004-10-27 Natrocell Technologies Ltd Composite rodenticide
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
EP1896076A2 (de) * 2005-06-27 2008-03-12 Daniel Drai Zusammensetzungen und verfahren zur verbesserung der sexualfunktion
US8227476B2 (en) 2005-08-03 2012-07-24 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
JP2009509984A (ja) * 2005-09-29 2009-03-12 バイエル・ヘルスケア・アクチェンゲゼルシャフト 泌尿器系障害の処置用のｐｄｅ阻害剤およびそれらの組合せ
CA2626134C (en) 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
EP1790343A1 (de) * 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmazeutische Zusammensetzungen und deren Verwendung zur Behandlung sexueller Störungen der Frau
US20090312242A1 (en) 2006-06-30 2009-12-17 Ramiro Castro Flibanserin for the treatment of urinary incontinence and related diseases
CA2660476C (en) 2006-08-14 2015-11-17 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
EP2056797A2 (de) 2006-08-25 2009-05-13 Boehringer Ingelheim International GmbH System mit kontrollierter freisetzung und verfahren zu seiner herstellung
EP1925307A1 (de) 2006-11-03 2008-05-28 Emotional Brain B.V. Verwendung von 3-alpha-androstanediol zur Behandlung sexueller Dysfunktion
WO2008115797A1 (en) * 2007-03-16 2008-09-25 Pavo, Inc. Therapeutic compositions and methods
KR20100029762A (ko) * 2007-06-13 2010-03-17 바이엘 쉐링 파마 악티엔게젤샤프트 청력 장애 치료용 ｐｄｅ 억제제
PE20091188A1 (es) 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen
WO2009098697A1 (en) * 2008-02-08 2009-08-13 Dexxon Ltd. Modafinil and sildenafil dosage forms
EP2374460A4 (de) 2008-12-12 2013-08-21 Rhein Siegfried Sa De Cv Sildenafil-zusammensetzung mit gepulster freisetzung und verfahren zur herstellung dieser zusammensetzung
KR101004205B1 (ko) * 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
EA015250B9 (ru) * 2010-11-19 2013-10-30 Тева Фармасьютикал Индастриз, Лтд. Таблетка силденафила, обеспечивающая модифицированную фармакокинетику, и способ ее изготовления
KR102158948B1 (ko) 2011-05-13 2020-09-24 이비 아이피 하이브리탭스 비.브이. 약물 전달 시스템
US20140328911A1 (en) * 2011-07-22 2014-11-06 Pom Wonderful. Llc Compositions comprising pomegranate polyphenols in combination with erectile dysfunction-treating compounds, and methods of treating erectile dysfunction therewith
WO2017168174A1 (en) * 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
CN113995727B (zh) * 2021-11-08 2023-04-07 山东鲁抗医药股份有限公司 一种5型磷酸二酯酶抑制剂片剂及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3952741A (en) 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
JPS54119021A (en) * 1978-03-06 1979-09-14 Nippon Kayaku Co Ltd Carcinostatic agent
CH648754A5 (en) * 1979-08-16 1985-04-15 Ciba Geigy Ag Pharmaceutical slow release tablet
JPS5748908A (en) * 1980-09-08 1982-03-20 Kyorin Pharmaceut Co Ltd Prolonged release type nicomol pharmaceutical
FR2624732B1 (fr) 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
MC2025A1 (fr) * 1988-04-20 1990-04-25 Asta Pharma Ag Medicament contenant de l'azelastine et capable de liberer celle-ci de facon controlee
IT1229856B (it) * 1989-04-20 1991-09-13 Recordati Chem Pharm Compresse a rilascio controllato contenenti flavossato.
US5474784A (en) 1990-03-02 1995-12-12 British Technology Group Limited Dispensing device
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
DE69425453T2 (de) * 1993-04-23 2001-04-12 Novartis Ag, Basel Wirkstoffabgabevorrichtung mit gesteuerter Freigabe
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US5464633A (en) 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
US5656629A (en) * 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
US5888534A (en) 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
WO1997048382A2 (en) * 1996-06-18 1997-12-24 Otsuka Pharmaceutical Co., Ltd. Multiple-unit type prolonged action drug preparation
JPH1067657A (ja) * 1996-06-18 1998-03-10 Otsuka Pharmaceut Co Ltd マルチプルユニット型持続性製剤
DE69721559T2 (de) * 1997-01-06 2003-11-27 Pfizer Inc., New York Geschmacksmaskierte pharmazeutische dosisform mit schneller freisetzung
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6277884B1 (en) * 1998-06-01 2001-08-21 Nitromed, Inc. Treatment of sexual dysfunction with N-hydroxyguanidine compounds
ATE264861T1 (de) * 1998-09-04 2004-05-15 Ortho Mcneil Pharm Inc 5-heterozyklyl-pyrazolo(4,3-d)pyrimidin-7-one für die behandlung von männlichen erectilen dysfunktionen

Also Published As

Publication number Publication date
BR9914718A (pt) 2001-07-10
ES2272082T3 (es) 2007-04-16
PL347476A1 (en) 2002-04-08
MA26700A1 (fr) 2004-12-20
IL141764A0 (en) 2002-03-10
GT199900184A (es) 2001-04-14
DZ2923A1 (fr) 2004-03-01
WO2000024383A1 (en) 2000-05-04
CA2348086C (en) 2007-01-23
AU756509B2 (en) 2003-01-16
IL141764A (en) 2008-06-05
BG65323B1 (bg) 2008-02-29
NZ510275A (en) 2003-07-25
NO20011933L (no) 2001-06-25
BG105465A (bg) 2001-12-29
CR6326A (es) 2004-02-23
US6964780B1 (en) 2005-11-15
JP2002528408A (ja) 2002-09-03
EP1123088A1 (de) 2001-08-16
OA11664A (en) 2005-01-07
IS5865A (is) 2001-02-27
HUP0104318A2 (hu) 2002-03-28
MXPA01004011A (es) 2003-03-10
UA67802C2 (uk) 2004-07-15
SK5192001A3 (en) 2002-09-10
KR20010075659A (ko) 2001-08-09
EE200100235A (et) 2002-08-15
CO5160262A1 (es) 2002-05-30
HK1041818A1 (zh) 2002-07-26
EP1123088B1 (de) 2006-09-27
TR200101103T2 (tr) 2001-09-21
NO20011933D0 (no) 2001-04-19
PA8484301A1 (es) 2000-09-29
DE69933383T2 (de) 2007-02-01
AP2001002125A0 (en) 2001-04-04
EA004068B1 (ru) 2003-12-25
CZ20011427A3 (cs) 2001-10-17
HRP20010285A2 (en) 2002-06-30
HUP0104318A3 (en) 2003-12-29
MY130727A (en) 2007-07-31
CA2348086A1 (en) 2000-05-04
DE69933383D1 (de) 2006-11-09
PE20001286A1 (es) 2000-11-22
PT1123088E (pt) 2007-01-31
CN1324233A (zh) 2001-11-28
SK286473B6 (sk) 2008-11-06
CY1106239T1 (el) 2011-06-08
EA200100298A1 (ru) 2001-08-27
AU5878799A (en) 2000-05-15
PL195789B1 (pl) 2007-10-31
ID28232A (id) 2001-05-10
UY25765A1 (es) 2001-08-27
TW577756B (en) 2004-03-01
DK1123088T3 (da) 2007-01-02

Similar Documents

Publication Publication Date Title
ATE340562T1 (de) Cgmp pde-5 inhibitor enthaltende pharmazeutische formulierungen mit verzögerter freisetzung
DE69924999D1 (de) Lipasehemmer enthaltende pharmazeutische zusammensetzungen
ATE320244T1 (de) Pharmazeutische zusammensetzungen mit amlodipinmaleat
IL155293A0 (en) Delayed release pharmaceutical formulations
DK1600154T3 (da) Osmotisk doseringsform med forlænget frigivelse
DE69807420D1 (de) Pharmazeutische aerosolzusammensetzung
DE69904312D1 (de) Pharmazeutische aerosolformulierung
ATE306253T1 (de) Orale bioadhäsive tablette mit verlängerter wirkstoffabgabe
ATE201986T1 (de) Kaffein-formulierung mit verzögerter freisetzung
EP1411904A4 (de) Pharmazeutische zusammensetzung mit verzögerter freisetzung
DE69721559D1 (de) Geschmacksmaskierte pharmazeutische dosisform mit schneller freisetzung
ATE254907T1 (de) Natriumhydrogendivalproat-formulierungen mit gesteuerter freigabe
ATE320807T1 (de) Pharmazeutische zusammensetzungen enthaltend tegaserod
DE69900561D1 (de) Pharmazeutische Zusammensetzungen enthaltend Mupirocin
NO20002126D0 (no) Formulering med forlenget frigjøring
HUP0301177A3 (en) Ion-strength independent sustained release pharmaceutical formulation
ATE350016T1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
DE59801987D1 (de) Pharmazeutische zusammensetzung enthaltend peptichemio
DE19983627T1 (de) Knoblauch-Formulierungen mit kontrollierter Freisetzung
ATE295150T1 (de) Pharmazeutische zusammensetzungen
NO984035L (no) Farmas°ytiske formuleringer med forlenget frigivelse inneholdende mizolastin
DE69816124D1 (de) Pharmazeutische zusammensetzungen enthaltend zafirlukast
ATE412405T1 (de) Pharmazeutische zusammensetzung mit modifiziertem träger
EP1124557A4 (de) Pharmazeutische zusammensetzung
DE10291905D2 (de) Pharmazeutische Zusammensetzung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1123088

Country of ref document: EP

REN Ceased due to non-payment of the annual fee